This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rump, L. C. Articles by Schollmeyer, P. J. Search for Related Content PubMed PubMed Citation Articles by Rump, L. C. Articles by Schollmeyer, P. J.

(Hypertension. 1995;26:445-451.)
© 1995 American Heart Association, Inc.

Articles

ß-Adrenergic, Angiotensin II, and Bradykinin Receptors Enhance Neurotransmission in Human Kidney

Lars C. Rump; Christine Bohmann; Ulrike Schaible; Wolfgang Schultze-Seemann; Peter J. Schollmeyer

From Innere Medizin IV und Urologie (W.S.-S.), Universitätsklinik Freiburg (Germany).

Abstract The aim of this study was to investigate angiotensin II (Ang II) receptor–, bradykinin receptor–, and ß-adrenergic receptor–mediated modulation of norepinephrine release from human renal sympathetic nerves and to characterize the respective receptor subtypes involved. Human cortical kidney slices were incubated with [³H]norepinephrine, placed in superfusion chambers between two platinum electrodes, and superfused with Krebs-Henseleit solution. The sympathetic nerves were stimulated electrically at 2.5 Hz for 1 minute, and the stimulation-induced outflow of radioactivity was taken as an index of endogenous norepinephrine release. Ang II and its precursor Ang I (both 0.01 to 1 µmol/L) enhanced stimulation-induced outflow of radioactivity in a concentration-dependent manner, with EC₅₀ values of 0.03 and 0.05 µmol/L, respectively. The enhancement by Ang I but not that by Ang II was inhibited by the angiotensin-converting enzyme inhibitor captopril (3 µmol/L). The concentration-response curves of Ang I and Ang II were shifted to the right by EXP 3174 (0.01 µmol), the in vitro active form of the Ang II type 1 receptor antagonist losartan, with affinity estimates of 8.72 and 9.30, respectively. A higher concentration of EXP 3174 (0.1 µmol/L) abolished the facilitatory effects of Ang I and Ang II. The Ang II type 2 receptor antagonist PD 123319 (10 µmol/L) did not alter the facilitation by Ang II. In the absence of other drugs, bradykinin (0.01 to 1 µmol/L) failed to modulate stimulation-induced outflow of radioactivity but in the presence of captopril (3 µmol/L) enhanced it in a concentration-dependent manner, with an EC₅₀ of 0.1 µmol/L. This facilitatory effect of bradykinin was prevented by the bradykinin type 2 receptor antagonist Hoe 140 (0.3 µmol/L). The ß₁/ß₂-adrenergic receptor agonist isoproterenol (0.001 to 0.1 µmol/L) also enhanced stimulation-induced outflow of radioactivity in a concentration-dependent manner, with an EC₅₀ of 0.008 µmol/L. The facilitatory effect of isoproterenol was abolished by the ß₂-adrenergic receptor antagonist ICI 118551 (0.03 µmoL/L) but unaltered by the ß₁-adrenergic receptor antagonist atenolol (3 µmol/L), captopril (3 µmol/L), or EXP 3174 (0.1 µmol/L). We conclude that activation of prejunctional Ang II type 1, bradykinin type 2, and ß₂-adrenergic receptors facilitates renal norepinephrine release in humans. Ang II can be formed locally within the human renal cortex from Ang I by angiotensin-converting enzyme to activate prejunctional Ang II type 1 receptors. The ß₂-adrenergic receptor–mediated effect is likely to function independently of a local renin-angiotensin system. However, the facilitatory bradykinin type 2 receptor mechanism can be demonstrated only when bradykinin degradation is prevented by the angiotensin-converting enzyme (kininase II) inhibitor captopril.

Key Words: kidney • human • norepinephrine • ß-adrenergic receptors • angiotensin II • bradykinin • losartan

This article has been cited by other articles:

				M. Byku, H. Macarthur, and T. C. Westfall Nerve stimulation induced overflow of neuropeptide Y and modulation by angiotensin II in spontaneously hypertensive rats Am J Physiol Heart Circ Physiol, November 1, 2008; 295(5): H2188 - H2197. [Abstract] [Full Text] [PDF]

				C. K. Ganta, N. Lu, B. G. Helwig, F. Blecha, R. R. Ganta, L. Zheng, C. R. Ross, T. I. Musch, R. J. Fels, and M. J. Kenney Central angiotensin II-enhanced splenic cytokine gene expression is mediated by the sympathetic nervous system Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1683 - H1691. [Abstract] [Full Text] [PDF]

				A. Dendorfer, A. Thornagel, W. Raasch, O. Grisk, K. Tempel, and P. Dominiak Angiotensin II Induces Catecholamine Release by Direct Ganglionic Excitation Hypertension, September 1, 2002; 40(3): 348 - 354. [Abstract] [Full Text] [PDF]

				S. Boehm and H. Kubista Fine Tuning of Sympathetic Transmitter Release via Ionotropic and Metabotropic Presynaptic Receptors Pharmacol. Rev., March 1, 2002; 54(1): 43 - 99. [Abstract] [Full Text] [PDF]

				Y. Kansui, K. Fujii, K. Goto, and I. Abe Bradykinin Enhances Sympathetic Neurotransmission in Rat Blood Vessels Hypertension, January 1, 2002; 39(1): 29 - 34. [Abstract] [Full Text] [PDF]

				E. Hatta, R. Maruyama, S. J. Marshall, M. Imamura, and R. Levi Bradykinin Promotes Ischemic Norepinephrine Release in Guinea Pig and Human Hearts J. Pharmacol. Exp. Ther., March 1, 1999; 288(3): 919 - 927. [Abstract] [Full Text]

				N. Seyedi, T. Win, H. M. Lander, and R. Levi Bradykinin B2-Receptor Activation Augments Norepinephrine Exocytosis From Cardiac Sympathetic Nerve Endings : Mediation by Autocrine/Paracrine Mechanisms Circ. Res., November 19, 1997; 81(5): 774 - 784. [Abstract] [Full Text]